NanoScope Technologies

Nanoscope Therapeutics Strengthens Clinical, Regulatory Expertise with Appointment of Chief Medical Officer

by | Sep 22, 2023
Samuel Barone, M.D., is a former Federal Drug Administration official and leader in the pharmaceutical space.
MORE
Nanoscope Therapeutics Bolsters Board with Addition of Ophthalmic Veteran as Strategic Adviser
by | Mar 22, 2023
Nanoscope Therapeutics has enlisted the expertise of Vicente Anido Jr., Ph.D. to help the company advance its goal of developing sight-restoring gene therapies for retinal degenerative diseases. Anido's appointment as a strategic adviser is expected to support Nanoscope's clinical and corporate strategies, especially as the company progresses towards the potential commercialization of MCO-010.
MORE
EYE DNA DALLAS STARTUP GENE THERAPY
Bedford Biotech Restores “Meaningful Vision” in Blind Patients With Gene Therapy—and May Soon Go Public
by | Jun 22, 2021
Nanoscope Therapeutics successfully treated 11 patients blinded by advanced retinitis pigmentosa (RP). A single intravitreal injection produced positive results that persisted through one year. The startup plans a Phase 2b trial this summer and plans to develop gene therapies to treat more common retinal diseases—like dry age-related macular degeneration.
MORE
prostate
Discovery: Fighting Prostate Cancer, Red Snapper in Gulf & Local Company Snags Orphan Drug Designation
by | Dec 29, 2017
Discoveries and breakthroughs happen all the time in North Texas laboratories and institutions. Here are some of their stories.
MORE
Protecting your privacy. We have strengthened our Privacy Policy to better protect you. This Policy includes our use of cookies to give you the best online experience and provide functionality essential to our services. By clicking ‘I Accept’ or by continuing to use our website, you are consenting to our Privacy Policy.